Research and Developments

Page 1 of 1912345...10...Last »

September 9, 2017

Lampalizumab for Dry AMD Unable to Meet Expectations in Phase III Trial

Posted in: Latest News, Research and Developments

Genentech has announced that the primary endpoint has not been met in Spectri, the first of two Phase III studies evaluating the safety and efficacy of lampalizumab. Lampalizumab, as reported here in July 2016, is an investigational medicine for the treatment of geographic atrophy (GA) due to age-related macular degeneration (AMD). It was designed to inhibit Complement Factor D,
read more »

August 29, 2017

All Avenues Need To Be Considered For Improving Vision

Posted in: Latest News, Research and Developments

Presbyopia and cataracts are the most prevalent vision-robbing conditions older people. A paper soon to be published in The Lancet (Volume 5, No. 9, e888–e897, September 2017) estimates that, in 2015, 36 million people in the world were blind and 217 million people were severely or moderately vision impaired. It also estimated that 1.1 billion
read more »

August 25, 2017

Promising Update on APL-2 for Dry AMD

Posted in: Latest News, Research and Developments

Statistically Significant Slowing of Disease Progression Seen at 12 Months APL-2 is a synthetic peptide which shuts down the complement activation system responsible for local inflammation, tissue damage (as in dry AMD) and the resulting blood vessel growth (angiogenesis in wet AMD). Discovered by Professor John Lambris, University of Pennsylvania, APL-2 (formerly called POT-4) was
read more »

July 22, 2017

Can We Trust Clinical Trials?

Posted in: Latest News, Research and Developments

An analysis published July 19 in Regenerative Medicine reminds us to be cautious about believing everything we read regarding clinical trials. A good case in point is our earlier report about three women who were blinded by an unproven stem cell treatment at a Florida clinic in 2015. They had been misled primarily by thinking that simply
read more »

July 6, 2017

Forgetfulness Can Actually Be Good For Us

Posted in: Latest News, Research and Developments

by Dan Roberts Research published in the June 2017 issue of the journal Neuron (1) suggests that loss of details in our memories may be beneficial to those of us who are visually impaired. Vision is eyesight, memory and logic working together. (2) Visually impaired individuals learn from experience that when eyesight is less clear,
read more »

June 1, 2017

New One-time Gene Therapy For Wet AMD Could Replace Regular Injections

Posted in: Latest News, Research and Developments

A new drug called RGX-314 is being developed as a one-time sub-retinal injection for wet AMD. This would be a significant improvement over current anti-VEGF therapies requiring repetitive and frequent intraocular injections. REGENXBIO Inc. has announced that the first human patient has been dosed in a phase I clinical trial of RGX-314. The drug has
read more »

May 23, 2017

Summary of Research and Developments–2017

Posted in: Daily Living, Latest News, Low Vision Rehabilitation, Research and Developments, Therapies, Treatments, and Procedures

Presentation to the International Low Vision Support Group June 1, 2017 Dan Roberts INTRODUCTION This is my 12th annual summary of leading research and developments occuring during the past 12 months in the fields of blindness and low vision. Sources for further information will appear beneath each topic heading, but for the sake of brevity,
read more »

April 24, 2017

Annual Eye Exams For Retinopathy May Be Unnecessary For Some Type 1 Diabetics

Posted in: Latest News, Research and Developments

Currently, patients who have had type 1 diabetes for 5 years are encouraged to have annual dilated retinal exams to look for possible progression to diabetic retinopathy (DR) or diabetic macular edema (DME). Both of these conditions can lead to severe vision loss and should be treated immediately. Now, a 30-year study* published in April
read more »

April 17, 2017

FDA Approves Lucentis® for Diabetic Retinopathy

Posted in: Latest News, Research and Developments

Genentech, Inc. has announced that the U.S. Food and Drug Administration (FDA) approved Lucentis® (ranibizumab injection) 0.3 mg for the monthly treatment of all forms of diabetic retinopathy. The most common cause of vision loss in people with diabetes, diabetic retinopathy is the leading cause of blindness among adults aged 20 to 74 and affects
read more »

April 15, 2017

New Sustained Delivery Method for Lucentis

Posted in: Latest News, Research and Developments

Genentech, Inc. is testing a less-invasive method of delivery of their anti-VEGF drug Lucentis into the eyes of patients with wet AMD. Currently, anti-VEGF treatments require regular monthly or bi-monthly injections into the back of the eye, which can be taxing on patients’ time and stress level. The new method utilizes a timed release capsule
read more »

Page 1 of 1912345...10...Last »

Custom Wordpress design and web development by Jeff Roberts Web Design

WP-Backgrounds by InoPlugs Web Design and Juwelier Schönmann